Evaluation of the efficacy, safety, and side effects of secukinumab in patients with moderate-to-severe psoriasis: real-world data from a retrospective multicenter study

Overview of attention for article published in Anais Brasileiros de Dermatologia, July 2022

Altmetric Badge

Mentioned by

So far, Altmetric has seen 1 news story.

At 12 weeks, nearly 8 in 10 patients had significant improvement. Secukinumab (Cosentyx) leads to significant improvement in…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity.